The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, but its future within the broader sector now presents questions about future gains. Alternative versions are diminishing market share, leading to anxieties that investing in companies heavily reliant to Viagra's previous position could be a dangerous